Wyeth reports dip in revenues; attributes flux to upheaval over kids’ cough-cold dosing
MADISON, N.J. Net revenues for Wyeth’s Worldwide Consumer Healthcare division fell 5 percent for the third quarter ending Sept. 30, the company reported Wednesday morning, primarily to a decrease in sales of Robitussin and Advil. Sales of Advil were down 7 percent to $165 million; and while Robitussin sales were not broken out specifically, the brand is one of several that have been negatively impacted over the confusion on whether or not pediatric cough-cold are safe and effective.
“The cough-cold market is changing considerably as illustrated” by the recent announcements from the Consumer Healthcare Products Association around voluntary label changes advising consumers not to give cough-cold medicines to children under the age of four and the January 2008 Food and Drug Administration announcement banning the marketing of these medicines to children under the age of two, commented Greg Norden, Wyeth senior vice president and chief financial officer, this morning during a call with analysts. Wyeth expects this business to rebound in the coming season, Norden noted.
“We’ve also launched a new product, Robitussin DM” to take advantage of a growing adult market, commented Cavan Redmond, president of Wyeth Consumer Healthcare.
The company’s dietary supplement franchise proved positive, however. Sales of Centrum were up 7 percent to $186 million.
Wyeth completed its acquisition of the Thermacare product line from Procter & Gamble last month and is expected to enhance Wyeth’s global position in pain management, the company stated.
Overall, worldwide net revenue increased 4 percent, to $5.8 billion, for the quarter. Excluding the favorable impact of foreign exchange, worldwide net revenue increased 2 percent.
Continua to demonstrate interoperable products at Connected Health symposium
PORTLAND, Ore. The Continua Health Alliance, an organization dedicated to enabling interoperable healthcare products and solutions, on Tuesday announced that the first demonstration of seamlessly connected Continua pre-certified products and solutions will take place Oct. 27 at the Partners Center for Connected Health 5th Annual Connected Health Symposium in Boston.
“With close to a quarter of the world’s population overweight, more than 600 million people with some form of chronic disease, and millions more reaching retirement age, the time for greater personal health management is now,” Dave Whitlinger, Continua Health Alliance president said. “Continua member companies are working on real solutions that will empower consumers and healthcare professionals to access and share information quickly and easily through connected products and solutions.”
A&D Medical, Cambridge Consultants, Cypak, FitLinxx, Google Health, IBM, Intel, National Health Service, Nonin Medical, Oracle, Partners, Philips, Roche Diagnostics and University Health Network will participate by providing devices and software solutions that support Continua’s upcoming Version One guidelines and share a common interface. The devices and solutions will be set in both home and professional settings. Audience members will see the benefits of real-time information sharing, including improved data for diagnostics and treatment, time and cost savings, and an improved patient experience.
Pharmaca stores collecting unused OTCs, supplements and more for disposal
BOULDER, Colo. Pharmaca Integrative Pharmacy has launched a pharmaceutical drop-off program at each of its 22 pharmacy locations.
Pharmacy customers may drop off their expired or unneeded prescription medications, expired vitamins and supplements, OTCs, needles and syringes and medication samples with the exception of controlled substances to the collection site, and Pharmaca will send all items to be destroyed, the company said in a release.